US 2020/0309780 A1 · PLASMA BIOMARKER FOR OVARIAN CANCER

Abstract

The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker Annexin A2 is higher in the plasma of subjects with early stage ovarian cancer. Accordingly, methods of detecting early stage ovarian cancer in a subject, of identifying a subject having early stage ovarian cancer, and of determining if a subject is susceptible to developing ovarian cancer, are provided. Also provided are methods of screening candidate therapeutic agents for use in treating early stage ovarian cancer, and compositions and kits for detecting early stage ovarian cancer in a subject, for identifying a subject having early stage ovarian cancer, and for determining if a subject is susceptible to developing ovarian cancer.

Claims13

Dependent claims

A method, including:

(a) assessing an expression level of Annexin A2 in plasma of a subject;
(b) comparing the expression level of Annexin A2 in the plasma with a reference expression level for Annexin A2;
and
(c) detecting an early stage ovarian cancer in the subject on the basis of the comparison,
wherein an expression level of Annexin A2 in the subject that is higher than the reference expression level for Annexin A2 is indicative of the early stage ovarian cancer in the subject;
and
(d) administering, to the subject, a candidate therapeutic agent for treating the early stage ovarian cancer.

4 more elements

Dependencies are inferred from the claim text.

Plasma biomarker for ovarian cancer

Life of this patent

Plasma biomarker for ovarian cancer

Life of this patent

Abstract

Claims13